IFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR EWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

BOX 1459, ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

OIPE

PATENT

Attorney's Docket No.: 00065.01R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hale et al.

Serial No.:

10/712,365

Filed: Title

DIURETIC AEROSOLS AND METHODS OF MAKING AND USING 11/12/2003

THEM

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

> P P / 4 LOU.	SEP	2	4	2004
----------------	-----	---	---	------

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905

FAX: (650) 687-3999

Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/712,365
TRANSMITTAL	Filing Date	11/12/2003
FORM	First Named Inventor	Ron L. Hale
(to be used for all correspondence after initial filing)	Art Unit	Not yet known
	Examiner Name	To be assigned
Total Number of Pages in This Submission	Attorney Docket Number	00065.01R

PTO/SB/21 (08-03)

		ENCLOSU	RES (check all that appl)	()		
Fee Transmittal Form		Drawing(s)			After Allowance communication to Group	
Fee Attached		Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences	
Amendment / Reply	Amendment / Reply Petition				Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final	nal Petition to Convert a Provisional Application				Proprietary Information	
Affidavits/declar	Affidavits/declaration(s) Power of Attomey, Revocation Change of Correspondence				Status Letter	
Extension of Time Request Terminal Disclaimer			Disclaimer	X	Other Enclosure(s) (please identify below):	
Express Abandonment F	Express Abandonment Request Request for Refund					
Information Disclosure S	Statement	CD, Number of CD(s)				
Certified Copy of Priority Document(s) Remarks				.Jl		
Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 Info. Discl. Statemetn (2 pp.) Form 1449 (3 copies, 4 pages each) Copy of 91 references Return Postcard						
	SIGNATUR	RE OF APPLICAN	T, ATTORNEY, OR AGEN	IT		
Firm or Individual name ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Elaine C. Stracker, Ph.D., J.D. Telephone (650)-687-3905 Customer Number 37485						
Signature Ham (Linda						
Date	Date SEP. 2 4 2004					

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the Typed or printed name Elaine C. Stracker SEP. 2 4 2004 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandria, VA 22313-1450.

1

ON DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R	Application Number: 10/712	,365

Applicant: HALE et al.

Filing Date: 11/12/2003 Group Art Unit: Unknown

			U.S. PATENT	DOCUMENTS			
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

1.	08/04/2003	10/633,876	Hale et al.
2.	08/04/2003	10/633,877	Hale et al.
3.	12/30/2003	10/749,537	Rabinowitz et al.
4.	12/30/2003	10/749,539	Rabinowitz et al.
5.	01/27/2004	10/766,149	Rabinowitz et al.
6.	01/27/2004	10/766,279	Rabinowitz et al.
7.	01/27/2004	10/766,566	Rabinowitz et al.
8.	01/27/2004	10/766,574	Rabinowitz et al.
9.	01/27/2004	10/766,634	Rabinowitz et al.
10	0. 01/27/2004	10/766,647	Rabinowitz et al.
1	1. 01/28/2004	10/767,115	Rabinowitz et al.
12	2. 01/29/2004	10/768,205	Rabinowitz et al.
1.	3. 01/29/2004	10/768,220	Rabinowitz et al.
14	4. 01/29/2004	10/768,281	Rabinowitz et al.
1:	5. 01/29/2004	10/768,293	Rabinowitz et al.
10	5. 01/30/2004	10/769,046	Rabinowitz et al.
1	7. 01/30/2004	10/769,051	Rabinowitz et al.
13	3. 01/29/2004	10/769,157	Rabinowitz et al.
19	9. 01/29/2004	10/769,197	Rabinowitz et al.
20	0. 02/09/2004	10/775,583	Rabinowitz et al.
2	1. 02/09/2004	10/775,586	Rabinowitz et al.
2:	2. 03/03/2004	10/791,915	Hale et al.
2:	3. 03/03/2004	10/792,001	Rabinowitz et al.

EXAMINER:

DATE CONSIDERED:

) ١

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

7	Docket Number: 00065.01R	Application Number: 10/712,365
١		
	Applicant: HALE et al.	
	11/2/2002	Group Art Unit: Unknown
	Filing Date: 11/12/2003	

		10/702 012	Hale et al.	
24.	03/03/2004	10/172,012	Rabinowitz et al.	
25.	03/03/2004	10/7/23020	Hale et al.	
26.	03/03/2004	10/792,070	Hale et al.	
27.	03/03/2004	10/192,237	Rabinowitz et al.	
28.	03/31/2004	10/813,721	Rabinowitz et al.	
29.	03/31/2004	10/813,722	Rabinowitz et al.	
30.	03/31/2004	10/814,690	Rabinowitz et al.	
31	17.1.17.00.4	10/814,998	Rabinowitz et al.	
32	. 04/01/2004	10/815,527	Rabinowitz et al.	
33	10.004	10/816,407	Rabinowitz et al.	
34	12.004	10/816,492		
35		10/816,567	Rabinowitz et al.	
30		10/912,462	Hale et al.	
3		US 2003/0015196	Hodges et al.	
$\frac{3}{3}$	10000	US 2003/0062042	Wensley et al.	
	9. 11/13/2003	US 2003/0209240	Hale et al.	
	0. 01/02/2003	US 2003/0000518	Rabinowitz et al.	
	1. 01/09/2003	US 2003/0005924		
	2. 01/09/2003	US 2003/0005925		
	13. 01/09/2003	US 2003/0007933		
	14. 01/09/2003	US 2003/0007934		
	45. 01/16/2003	US 2003/0012737		
	46. 01/16/2003	US 2003/0012738		
	47. 1/16/2003	US 2003/0012740		
	48. 01/23/2003	US 2003/0015189		
	49. 01/23/2003	US 2003/0015190		
	50. 01/23/2003	US 2003/001711		
	51. 01/23/2003	US 2003/001711		
	52. 01/23/2003	US 2003/001711		
	53. 01/23/2003	US 2003/001711	7 Rabinowitz et al.	
	54. 01/23/2003	US 2003/001711	8 Rabinowitz et al. DATE CONSIDERED:	

EXAMINER:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	Bheet 5 ez -
Docket Number: 00065.01R	Application Number: 10/712,365
Applicant: HALE et al.	
Filing Date: 11/12/2003	Group Art Unit: Unknown
Filling Date: Thria	

	55.	01/23/2003	US 2003/0017119	Rabinowitz et al.
	56.	01/23/2003	US 2003/0017120	Rabinowitz et al.
	57.	1/30/2003	US 2003/0021753	Rabinowitz et al.
	58.	01/30/2003	US 2003/0021754	Rabinowitz et al.
	59.	01/30/2003	US 2003/0021755	Hale et al.
	60.	02/20/2003	US 2003/0035776	Hodges et al.
	61.	05/15/2003	US 2003/0091511	Rabinowitz et al.
	62.	05/27/2004	US 2004/010148	Hale et al.
	63.	07/31/2003	US 2003/0138382	Rabinowitz
	64.	11/06/2003	US 2003/0206869	Rabinowitz et al.
	65.	01/15/2004	US 2004/0009128	Rabinowitz et al.
	66.	05/20/2004	US 2004/0096402	Hodges et al.
	67.	05/27/2004	US 2004/0099269	Hale et al.
<u> </u>	68.	06/03/2004	US 2004/0105819	Hale et al.
	69.	07/01/2004	US 2004/0126326	
	70.		US 2004/0126327	Rabinowitz et al.
<u></u>	71		US 2004/0126328	
	72		US 2004/0126329	
	73		US 2004/0127481	
	74		US 2004/0127490	
	75		US 2004/0156788	
	76		US 2004/0156789	
	77		US 2004/0156790	
	78		US 2004/0156791	Rabinowitz et al.

FOREIGN PATENT DOCUMENTS

			FOREIGN PATE	NI DOCOMENTS	Class	Subclass	Translation
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	YES NO
				DATE CONSIDER	ED:		

EXAMINER:

)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets i	if necessary)
-----------------------	---------------

Docket Number: 00065.01R	Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003 Group Art Unit: Unknown

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." European Journal of Pharmaceutics and Biopharmaceutics Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." Cardiovascular Research 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" International Journal of Pharmaceutics 204:35-41.
	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." Am J Respir Crit Care Med Vol. 161: 1963-1967.
	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." Am. Rev. Repir. Dis. 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." Br J Clin Pharmacol Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5'Monophosphate Airway Responsiveness with Inahled Furosemide and Bumetanide in Asthma." J. Allergy Clin. Immunol. 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oygenase Products." <i>Eur. Respir. J</i> 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." Am J Physiol Renal Pysiol. 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." Journal of Pain and Symptom Management Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next	

TION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	Sheet 1 e2 :		
Docket Number: 00065.01R Application Number: 10/712,3			
Applicant: HALE et al.			
Filing Date: 11/12/2003	Group Art Unit: Unknown		

				T DOCUMENTS Name	Class	Subclass	Filing Date If Appropriate
Examiner Initials	Ref. No.	Date	Document No.				Арргорпас
							(T) ITC

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS Hale et al. 10/633,876 08/04/2003 Hale et al. 10/633,877 08/04/2003 2. Rabinowitz et al. 10/749,537 12/30/2003 3. Rabinowitz et al. 10/749,539 12/30/2003 4. Rabinowitz et al. 10/766,149 01/27/2004 5. Rabinowitz et al. 10/766,279 01/27/2004 6. Rabinowitz et al. 10/766,566 01/27/2004 7. Rabinowitz et al. 10/766,574 01/27/2004 8. Rabinowitz et al. 10/766,634 01/27/2004 9. Rabinowitz et al. 10/766,647 01/27/2004 10. Rabinowitz et al. 10/767,115 01/28/2004 11. Rabinowitz et al. 10/768,205 01/29/2004 12. Rabinowitz et al. 10/768,220 01/29/2004 13. Rabinowitz et al. 10/768,281 01/29/2004 14. Rabinowitz et al. 10/768,293 01/29/2004 15. Rabinowitz et al. 10/769,046 01/30/2004 16. Rabinowitz et al. 10/769,051 01/30/2004 17. Rabinowitz et al. 10/769,157 01/29/2004 18. Rabinowitz et al. 10/769,197 01/29/2004 19. Rabinowitz et al. 10/775,583 02/09/2004 20. Rabinowitz et al. 10/775,586 02/09/2004 21. Hale et al. 10/791,915 03/03/2004 22. Rabinowitz et al. 10/792,001 03/03/2004 23.

	23.	03/03/2004	10/172,001	Rabino	
				DATE CONSIDERED:	
EXAN	MINER:			the design of noting	
				of the citation of not in	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003 Group Art Unit: Unknown

			W 14-1
24.	03/03/2004	10/792,012	Hale et al.
25.	03/03/2004	10/792,013	Rabinowitz et al.
26.	03/03/2004	10/792,096	Hale et al.
27.	03/03/2004	10/792,239	Hale et al.
28.	03/31/2004	10/813,721	Rabinowitz et al.
29.	03/31/2004	10/813,722	Rabinowitz et al.
30.	03/31/2004	10/814,690	Rabinowitz et al.
31.	03/31/2004	10/814,998	Rabinowitz et al.
32.	04/01/2004	10/815,527	Rabinowitz et al.
33.	04/01/2004	10/816,407	Rabinowitz et al.
34.	04/01/2004	10/816,492	Rabinowitz et al.
35.	04/01/2004	10/816,567	Rabinowitz et al.
36.	08/04/2004	10/912,462	Hale et al.
37.	01/23/2003	US 2003/0015196	Hodges et al.
38.	04/03/2003	US 2003/0062042	Wensley et al.
39.	11/13/2003	US 2003/0209240	Hale et al.
40.	01/02/2003	US 2003/0000518	Rabinowitz et al.
41.	01/09/2003	US 2003/0005924	Rabinowitz et al.
42.	01/09/2003	US 2003/0005925	Hale et al.
43.	01/09/2003	US 2003/0007933	Rabinowitz et al.
44.	01/09/2003	US 2003/0007934	Rabinowitz et al.
45.	01/16/2003	US 2003/0012737	Rabinowitz et al.
46.	01/16/2003	US 2003/0012738	Rabinowitz et al.
47.	1/16/2003	US 2003/0012740	Rabinowitz et al.
48.		US 2003/0015189	Rabinowitz et al.
49	01/23/2003	US 2003/0015190	Rabinowitz et al.
50		US 2003/0017114	Rabinowitz et al.
51		US 2003/0017115	Rabinowitz et al.
52		US 2003/0017116	Rabinowitz et al.
53		US 2003/0017117	Rabinowitz et al.
54		US 2003/0017118	Rabinowitz et al.

EXAMINER:

DATE CONSIDERED:

Form	PTO-1	449
------	-------	-----

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R	Application Number: 10/712,365
Applicant: HALE et al.	
Filing Date: 11/12/2003	Group Art Unit: Unknown

	T 55	01/23/2003	US 2003/0017119	Rabinowitz et al.
	1	01/23/2003	US 2003/0017120	Rabinowitz et al.
	57.	1/30/2003	US 2003/0021753	Rabinowitz et al.
	58.	01/30/2003	US 2003/0021754	Rabinowitz et al.
	59.	01/30/2003	US 2003/0021755	Hale et al.
	60.	02/20/2003	US 2003/0035776	Hodges et al.
	61.	05/15/2003	US 2003/0091511	Rabinowitz et al.
	62.	05/27/2004	US 2004/010148	Hale et al.
	63.	07/31/2003	US 2003/0138382	Rabinowitz
	64.	11/06/2003	US 2003/0206869	Rabinowitz et al.
	65.	01/15/2004	US 2004/0009128	Rabinowitz et al.
	66.	05/20/2004	US 2004/0096402	Hodges et al.
	67.	17.4.4	US 2004/0099269	Hale et al.
	68.	06/03/2004	US 2004/0105819	
	69.		US 2004/0126326	
	70.		US 2004/0126327	
	71		US 2004/0126328	
	72		US 2004/0126329	
·	73	. 07/01/2004	US 2004/0127481	
	74		US 2004/0127490	
	75	. 08/12/2004	US 2004/0156788	
	76	5. 08/12/2004	US 2004/0156789	
	77	7. 8/12/2004	US 2004/0156790	
	78	3. 08/12/2004	US 2004/0156791	1 Rabinowitz et al.

FOREIGN PATENT DOCUMENTS

				O DOCUMENTS	Class	Subclass	Translation
Examiner	Ref.	Date	Document No.	Country	Class	0.000	YES NO
Initials	No.						
				DATE CONSIDER	ED:		

EXAMINER:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R	Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003 Group Art Unit: Unknown

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." European Journal of Pharmaceutics and Biopharmaceutics Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." Cardiovascular Research 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
r	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" International Journal of Pharmaceutics 204:35-41.
	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." Am J Respir Crit Care Med Vol. 161: 1963-1967.
-	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." Am. Rev. Repir. Dis. 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." Br J Clin Pharmacol Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5'Monophosphate Airway Responsiveness with Inahled Furosemide and Bumetanide in Asthma." J. Allergy Clin. Immunol. 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oygenase Products." <i>Eur. Respir. J</i> 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." Am J Physiol Renal Pysiol. 283:F11-21.
1	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." Journal of Pain and Symptom Management Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:

SEP 2 1 2004 F

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R	Application Number: 10/712,365
Applicant: HALE et al.	
Filing Date: 11/12/2003	Group Art Unit: Unknown

,			U.S. PATENT	DOCUMENTS			
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
			·			,	

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS Hale et al. 10/633,876 08/04/2003 Hale et al. 10/633,877 08/04/2003 2. Rabinowitz et al. 10/749,537 3. 12/30/2003 Rabinowitz et al. 12/30/2003 10/749,539 4. Rabinowitz et al. 10/766,149 01/27/2004 5. Rabinowitz et al. 10/766,279 6. 01/27/2004 Rabinowitz et al. 10/766,566 7. 01/27/2004 Rabinowitz et al. 10/766,574 01/27/2004 8. Rabinowitz et al. 10/766,634 01/27/2004 9. Rabinowitz et al. 10/766,647 01/27/2004 10. Rabinowitz et al. 10/767,115 11. 01/28/2004 Rabinowitz et al. 10/768,205 01/29/2004 12. Rabinowitz et al. 10/768,220 01/29/2004 13. Rabinowitz et al. 10/768,281 01/29/2004 14. Rabinowitz et al. 10/768,293 01/29/2004 15. Rabinowitz et al. 10/769,046 01/30/2004 16. Rabinowitz et al. 10/769,051 01/30/2004 17. Rabinowitz et al. 10/769,157 18. 01/29/2004 Rabinowitz et al. 10/769,197 01/29/2004 19. Rabinowitz et al. 10/775,583 20. 02/09/2004 Rabinowitz et al. 10/775,586 02/09/2004 21. 10/791,915 Hale et al. 03/03/2004 22. Rabinowitz et al. 10/792,001 03/03/2004 23.

FY	Δ λ.	/TN	IFE	•

DATE CONSIDERED:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Application Number: 10/712,365 Docket Number: 00065.01R

Applicant: HALE et al.

Group Art Unit: Unknown Filing Date: 11/12/2003

 24. 0	3/03/2004	10///2,012	Hale et al.	├		
	3/03/2004	10/1/23010	Rabinowitz et al.			
 1 20.	3/03/2004	10/172,070	Hale et al.			-
 1	3/03/2004	10///2,23/	Hale et al.			
 1 -11	3/31/2004	10/813,721	Rabinowitz et al.			
 	3/31/2004	10/813,722	Rabinowitz et al.	 		
 	3/31/2004	10/814,690	Rabinowitz et al.	ļ		
 1 30.1)3/31/2004	10/814,998	Rabinowitz et al.			
)4/01/2004	10/815,527	Rabinowitz et al.			
1	04/01/2004	10/816,407	Rabinowitz et al.		ļ	
 1 22.1	04/01/2004	10/816,492	Rabinowitz et al.		ļ	
1 *	04/01/2004	10/816,567	Rabinowitz et al.			
	08/04/2004	10/912,462	Hale et al.			
 30.	01/23/2003	US 2003/0015196	Hodges et al.	<u> </u>		
 1 2	04/03/2003	US 2003/0062042	Wensley et al.			
 39.	11/13/2003	US 2003/0209240	Hale et al.			
 · · · · · · · · · · · · · · · · · · ·	01/02/2003	US 2003/0000518	Rabinowitz et al.	_		
 41.	01/09/2003	US 2003/0005924	Rabinowitz et al.			
 42.	01/09/2003	US 2003/0005925	Hale et al.			
 43.	01/09/2003	US 2003/0007933	Rabinowitz et al.			
 44.	01/09/2003	US 2003/0007934	Rabinowitz et al.		_	
45.	01/16/2003	US 2003/0012737	Rabinowitz et al.		_	
 46.	01/16/2003	US 2003/0012738	Rabinowitz et al.			-
 47.	1/16/2003	US 2003/0012740				
 48.	01/23/2003	US 2003/0015189	Rabinowitz et al.			
 49.	01/23/2003	US 2003/0015190			_	
 50.		US 2003/0017114				
 51.	01/23/2003	US 2003/0017115	Rabinowitz et al.			
 52.		US 2003/0017116	Rabinowitz et al.			
 53.		US 2003/0017117	Rabinowitz et al.			
 54.	12000	US 2003/0017118	Rabinowitz et al. DATE CONSIDE			

EXAMINER:

FOIR F 10-17-7	Form	PTC	-1449
----------------	------	-----	-------

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	Sheet 5
Docket Number: 00065.01R	Application Number: 10/712,365
Applicant: HALE et al.	
Filing Date: 11/12/2003	Group Art Unit: Unknown
Filing Date: 11/12/2000	

	55.	01/23/2003	US 2003/0017119	Rabinowitz et al.			
	56.	01/23/2003	US 2003/0017120	Rabinowitz et al.			
	57.	1/30/2003	US 2003/0021753	Rabinowitz et al.			
	58.	01/30/2003	US 2003/0021754	Rabinowitz et al.	ļ		
	59.	01/30/2003	US 2003/0021755	Hale et al.			
	60.	02/20/2003	US 2003/0035776	Hodges et al.	<u> </u>		
	61.	05/15/2003	US 2003/0091511	Rabinowitz et al.		 	
	62.	05/27/2004	US 2004/010148	Hale et al.			
	63.	07/31/2003	US 2003/0138382	Rabinowitz		 	
	64.	11/06/2003	US 2003/0206869	Rabinowitz et al.	ļ	 	
	65.	01/15/2004	US 2004/0009128	Rabinowitz et al.	 -		
	66.	05/20/2004	US 2004/0096402	Hodges et al.			
	67.		US 2004/0099269	Hale et al.			
	68.		US 2004/0105819	Hale et al.			
	69.		US 2004/0126326	Rabinowitz et al.			
	70		US 2004/0126327	Rabinowitz et al.		 	
	$\frac{71}{71}$		US 2004/0126328	Rabinowitz et al.			
	72		US 2004/0126329	Rabinowitz et al.			
•	73		US 2004/0127481	Rabinowitz et al.			
	74		US 2004/0127490			_	
	75		US 2004/0156788				
	76		US 2004/0156789				
	7		US 2004/0156790				
	- 7 8		US 2004/0156791	Rabinowitz et al.			

FOREIGN PATENT DOCUMENTS

			FOREIGN PATE	NI DOCUMENTS	Class	Subclass	Translation
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Suociass	YES NO
				DATE CONSIDER	ED:		

EXAMINER:

DATE CONSIDERED:

	•	Differ 1 of			
Form PTO-1	449	Docket Number: 00065.01R	Application Number: 10/712,365		
INFOR	MATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: HALE et al.			
•	(Use several sheets if necessary)	Filing Date: 11/12/2003	Group Art Unit: Unknown		

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." European Journal of Pharmaceutics and Biopharmaceutics Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." Cardiovascular Research 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
•	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" International Journal of Pharmaceutics 204:35-41.
•	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." Am J Respir Crit Care Med Vol. 161: 1963-1967.
-	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." Am. Rev. Repir. Dis. 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." Br J Clin Pharmacol Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5'Monophosphate Airway Responsiveness with Inahled Furosemide and Bumetanide in Asthma." J. Allergy Clin. Immunol. 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oygenase Products." <i>Eur. Respir. J</i> 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." Am J Physiol Renal Pysiol. 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." Journal of Pain and Symptom Management Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in	